Christopher Gerard - Feb 17, 2022 Form 4 Insider Report for AMEDISYS INC (AMED)

Role
President & COO
Signature
/s/ Jennifer R. Guckert, pursuant to a power of attorney
Stock symbol
AMED
Transactions as of
Feb 17, 2022
Transactions value $
-$291,592
Form type
4
Date filed
2/22/2022, 08:02 PM
Previous filing
Aug 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMED Common Stock Award $0 +6.11K +16.14% $0.00 44K Feb 17, 2022 Direct F1
transaction AMED Common Stock Tax liability -$292K -2.07K -4.7% $141.07 41.9K Feb 20, 2022 Direct
holding AMED Common Stock 279 Feb 17, 2022 Through 401(k) Plan F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMED Stock Option (Right to Buy) Award $0 +14.3K $0.00 14.3K Feb 17, 2022 Common Stock 14.3K $143.25 Direct F3
transaction AMED Restricted Stock Unit (Performance-Based Vesting) Award $0 +12.2K $0.00 12.2K Feb 17, 2022 Common Stock 12.2K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer awarded the Reporting Person 6,109 time-based RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest in equal, 25% installments on each of February 20, 2023, 2024, 2025 and 2026, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the RSUs.
F2 The information in this report is based on a plan statement dated as of December 31, 2021.
F3 The Stock Options are subject to time-based vesting conditions and will vest in equal, 25% installments on each of February 20, 2023, 2024, 2025 and 2026, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options.
F4 The performance-based RSUs will vest based on certification of achievement of an identified performance measure for 2022, with additional time-based vesting in equal 25% installments on each of the certification date and February 20, 2024, 2025 and 2026, assuming the Reporting Person remains continuously employed on the vesting date. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved.